Integrating rapamycin with novel PI3K/Akt/mTOR inhibitor microRNAs on NOTCH1-driven T-cell acute lymphoblastic leukemia (T-ALL)

Fateme Arjmand ¹ , Samaneh Shojaei ², Mitra Khalili ^3,1, Hossein Dinmohammadi ¹, Behzad Poopak ⁴, Samira Mohammadi-Yeganeh ^2,5 * , Yousef Mortazavi ^3,6 *

Cited by CrossRef: 0

1- Yao Q, Chen J, Luo M, Lin Z, Wang H, Fu X. A Novel TAL2::TCRB Fusion With PI3K/AKT Pathway Mutations in Pediatric T‐Cell Acute Lymphoblastic Leukemia: Diagnostic and Therapeutic Implications. Pediatric Blood & Cancer. 2025; [Crossref]

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate (2024): 20%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded; Google Scholar; SJR; Essential Science Indicators; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO
Member of COPE
Follower of ICMJE
Permission: Creative Commons